{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:08:22Z","timestamp":1785305302335,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"crossref","award":["CAMS-12M"],"award-info":[{"award-number":["CAMS-12M"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alpha-fetoprotein (AFP) plays a crucial role in the management of malignant ovarian germ cell tumors (MOGCTs) and is an important reference index for chemotherapy termination. However, a high level of AFP can also be caused by several benign diseases, causing confusion and impacting treatment decisions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We described four patients who were diagnosed with MOGCTs; the histologic subtype in two of them was mixed MOGCTs (yolk sac tumor with mature teratoma), while the rest was immature teratoma. The serum AFP level of each patient was abnormal before surgery, but it was still persistently elevated around 300\u2009ng\/ml even after additional cycles of chemotherapy. All patients were thoroughly evaluated, but we did not find any evidence of disease progression or residual tumors. Liver function tests were normal, whereas serum assays revealed positive of hepatitis B surface antigen, and two patients had a high level of HBV-DNA. They were chronic carriers of hepatitis B virus and never received relevant treatments. Then they were managed with tumor surveillance and the antiviral treatment. Thereafter, the AFP levels presented a slowly decreasing trend.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>False elevation of AFP in MOGCTs is a rare condition and should be assessed with a comprehensive evaluation to avoid unnecessary treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-019-0598-x","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T15:03:41Z","timestamp":1576249421000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Persistently elevated alpha-fetoprotein associated with chronic hepatitis B during chemotherapy for malignant ovarian germ cell tumors: a case series and a review of the literature"],"prefix":"10.1186","volume":"12","author":[{"given":"Xuan","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-1136","authenticated-orcid":false,"given":"Jia-Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"issue":"9 Suppl 3","key":"598_CR1","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1097\/IGC.0000000000000223","volume":"24","author":"J Brown","year":"2014","unstructured":"Brown J, Friedlander M, Backes FJ, Harter P, O\u2019Connor DM, de la Motte RT, Lorusso D, Maenpaa J, Kim JW, Tenney ME, et al. Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S48\u201354.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"598_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.bpobgyn.2012.01.002","volume":"26","author":"JJ Low","year":"2012","unstructured":"Low JJ, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumours. Best Pract Res Clin Obstet Gynaecol. 2012;26(3):347\u201355.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"8","key":"598_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","volume":"17","author":"DK Armstrong","year":"2019","unstructured":"Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Cancer Netw. 2019;17(8):896\u2013909.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"598_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.ejso.2006.07.010","volume":"32","author":"P Dallenbach","year":"2006","unstructured":"Dallenbach P, Bonnefoi H, Pelte MF, Vlastos G. Yolk sac tumours of the ovary: an update. Eur J Surg Oncol. 2006;32(10):1063\u201375.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"598_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.1990.8.4.715","volume":"8","author":"DM Gershenson","year":"1990","unstructured":"Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG, Wharton JT. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990;8(4):715\u201320.","journal-title":"J Clin Oncol"},{"issue":"4","key":"598_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1200\/JCO.1994.12.4.701","volume":"12","author":"S Williams","year":"1994","unstructured":"Williams S, Blessing JA, Liao SY, Ball H, Hanjani P. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12(4):701\u20136.","journal-title":"J Clin Oncol"},{"issue":"2","key":"598_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1097-0142(20000715)89:2<391::AID-CNCR26>3.0.CO;2-V","volume":"89","author":"JJ Low","year":"2000","unstructured":"Low JJ, Perrin LC, Crandon AJ, Hacker NF. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000;89(2):391\u20138.","journal-title":"Cancer"},{"issue":"2","key":"598_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ygyno.2016.08.329","volume":"143","author":"DM Gershenson","year":"2016","unstructured":"Gershenson DM, Frazier AL. Conundrums in the management of malignant ovarian germ cell tumors: Toward lessening acute morbidity and late effects of treatment. Gynecol Oncol. 2016;143(2):428\u201332.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"598_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ygyno.2013.08.016","volume":"131","author":"Q Liu","year":"2013","unstructured":"Liu Q, Ding X, Yang J, Cao D, Shen K, Lang J, Zhang G, Xin X, Xie X, Wu Y. The significance of comprehensive staging surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2013;131(3):551\u20134.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"598_CR10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jpedsurg.2003.11.027","volume":"39","author":"D Billmire","year":"2004","unstructured":"Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, Davis M, Giller R, Lauer S, Olson T, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg. 2004;39(3):424\u20139 discussion 424\u2013429.","journal-title":"J Pediatr Surg"},{"issue":"4","key":"598_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/bjc.2011.267","volume":"105","author":"H Mahdi","year":"2011","unstructured":"Mahdi H, Swensen RE, Hanna R, Kumar S, Ali-Fehmi R, Semaan A, Tamimi H, Morris RT, Munkarah AR. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer. 2011;105(4):493\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"598_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ygyno.2017.08.013","volume":"147","author":"D Nasioudis","year":"2017","unstructured":"Nasioudis D, Chapman-Davis E, Frey MK, Caputo TA, Holcomb K. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol. 2017;147(2):296\u2013301.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"598_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ygyno.2016.07.005","volume":"142","author":"RT de la Motte","year":"2016","unstructured":"de la Motte RT, Pautier P, Genestie C, Rey A, Gouy S, Leary A, Haie-Meder C, Kerbrat P, Culine S, Fizazi K, et al. Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors. Gynecol Oncol. 2016;142(3):452\u20137.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"598_CR14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2010.08.012","volume":"47","author":"RT de La Motte","year":"2011","unstructured":"de La Motte RT, Pautier P, Rey A, Duvillard P, Kerbrat P, Troalen F, Morice P, Haie-Meder C, Culine S, Lhomme C. Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases. Eur J Cancer (Oxford, England: 1990). 2011;47(2):175\u201382.","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"598_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1200\/EDBK_201139","volume":"38","author":"DR Feldman","year":"2018","unstructured":"Feldman DR. State-of-the-Art Management of Germ Cell Tumors. Am Soc Clin Oncol Educ Book. 2018;38:319\u201323.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16","key":"598_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/jnci\/djq245","volume":"102","author":"PS Grimison","year":"2010","unstructured":"Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010;102(16):1253\u201362.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"598_CR17","doi-asserted-by":"crossref","first-page":"15952","DOI":"10.18632\/oncotarget.15021","volume":"8","author":"Q Zhao","year":"2017","unstructured":"Zhao Q, Cao D, Yu M, Yang J, Liu Y, Xiang Y, Wu M, Pan L, Lang J, Xu K, et al. Safety and efficacy of bleomycin\/pingyangmycin-containing chemotherapy regimens for malignant germ cell tumor patients in the female genital system. Oncotarget. 2017;8(9):15952\u201315,960.","journal-title":"Oncotarget"},{"issue":"4","key":"598_CR18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/annonc\/mdx012","volume":"28","author":"KM Wymer","year":"2017","unstructured":"Wymer KM, Daneshmand S, Pierorazio PM, Pearce SM, Harris KT, Eggener SE. Mildly elevated serum alpha-fetoprotein (AFP) among patients with testicular cancer may not be associated with residual cancer or need for treatment. Ann Oncol. 2017;28(4):899\u2013902.","journal-title":"Ann Oncol"},{"issue":"5","key":"598_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s12094-014-1161-2","volume":"16","author":"J Aparicio","year":"2014","unstructured":"Aparicio J. Spanish Germ Cell Cancer G: Positron emission tomography (PET) is not indicated in the postchemotherapy evaluation of advanced non-seminomatous testicular germ cell tumors. Clin Transl Oncol. 2014;16(5):509\u201310.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"598_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/0378-1119(82)90210-4","volume":"20","author":"WG Beattie","year":"1982","unstructured":"Beattie WG, Dugaiczyk A. Structure and evolution of human alpha-fetoprotein deduced from partial sequence of cloned cDNA. Gene. 1982;20(3):415\u201322.","journal-title":"Gene"},{"issue":"4","key":"598_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/adc.2011.213181","volume":"96","author":"MJ Murray","year":"2011","unstructured":"Murray MJ, Nicholson JC. alpha-Fetoprotein. Arch Dis Child Educ Pract Ed. 2011;96(4):141\u20137.","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"5","key":"598_CR22","first-page":"979","volume":"32","author":"D Gitlin","year":"1972","unstructured":"Gitlin D, Perricelli A, Gitlin GM. Synthesis of -fetoprotein by liver, yolk sac, and gastrointestinal tract of the human conceptus. Cancer Res. 1972;32(5):979\u201382.","journal-title":"Cancer Res"},{"issue":"5334","key":"598_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/235161a0","volume":"235","author":"E Ruoslahti","year":"1972","unstructured":"Ruoslahti E, Seppala M. Foetoprotein in normal human serum. Nature. 1972;235(5334):161\u20132.","journal-title":"Nature"},{"issue":"3","key":"598_CR24","doi-asserted-by":"publisher","first-page":"e27512","DOI":"10.1002\/pbc.27512","volume":"66","author":"M Lockley","year":"2019","unstructured":"Lockley M, Stoneham SJ, Olson TA. Ovarian cancer in adolescents and young adults. Pediatr Blood Cancer. 2019;66(3):e27512.","journal-title":"Pediatr Blood Cancer"},{"key":"598_CR25","doi-asserted-by":"publisher","first-page":"893103","DOI":"10.1155\/2012\/893103","volume":"2012","author":"Q Lai","year":"2012","unstructured":"Lai Q, Melandro F, Pinheiro RS, Donfrancesco A, Fadel BA, Levi Sandri GB, Rossi M, Berloco PB, Frattaroli FM. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol. 2012;2012:893103.","journal-title":"Int J Hepatol"},{"issue":"8","key":"598_CR26","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1002\/1097-0142(19931015)72:8<2491::AID-CNCR2820720829>3.0.CO;2-0","volume":"72","author":"JR Germa","year":"1993","unstructured":"Germa JR, Llanos M, Tabernero JM, Mora J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer. 1993;72(8):2491\u20134.","journal-title":"Cancer"},{"issue":"2","key":"598_CR27","doi-asserted-by":"publisher","first-page":"e5844","DOI":"10.1097\/MD.0000000000005844","volume":"96","author":"CY Kim","year":"2017","unstructured":"Kim CY, Kim BR, Lee SS, Jeon DH, Lee CM, Kim WS, Cho HC, Kim JJ, Lee JM, Kim HJ, et al. Clinical features of hepatitis B and C virus infections, with high alpha-fetoprotein levels but not hepatocellular carcinoma. Medicine. 2017;96(2):e5844.","journal-title":"Medicine"},{"issue":"10","key":"598_CR28","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/elps.1150191039","volume":"19","author":"K Taketa","year":"1998","unstructured":"Taketa K. Multimodal application of lectin affinity electrophoresis of alpha-fetoprotein. Electrophoresis. 1998;19(10):1774\u20139.","journal-title":"Electrophoresis"},{"issue":"1","key":"598_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000217540","volume":"9","author":"J Breborowicz","year":"1988","unstructured":"Breborowicz J. Microheterogeneity of human alphafetoprotein. Tumour Biol. 1988;9(1):3\u201314.","journal-title":"Tumour Biol"},{"issue":"9","key":"598_CR30","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.bbagen.2011.12.015","volume":"1820","author":"H Korekane","year":"2012","unstructured":"Korekane H, Hasegawa T, Matsumoto A, Kinoshita N, Miyoshi E, Taniguchi N. Development of an antibody-lectin enzyme immunoassay for fucosylated alpha-fetoprotein. Biochim Biophys Acta. 2012;1820(9):1405\u201311.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"598_CR31","first-page":"133","volume":"51","author":"M Funahashi","year":"2005","unstructured":"Funahashi M, Tuchiya F, Makiyama K, Sugiura S, Miyoshi Y, Kishida T, Ogawa T, Uemura H, Yao M, Kubota Y. Two cases of testicular tumors with high alpha-fetoprotein levels: a case report. Hinyokika Kiyo Acta urologica Japonica. 2005;51(2):133\u20137.","journal-title":"Hinyokika Kiyo Acta urologica Japonica"},{"issue":"3","key":"598_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000478706","volume":"99","author":"KP Dieckmann","year":"2017","unstructured":"Dieckmann KP, Anheuser P, Simonsen H, Hoflmayer D. Pure Testicular Seminoma with Non-Pathologic Elevation of Alpha Fetoprotein: A Case Series. Urologia internationalis. 2017;99(3):353\u20137.","journal-title":"Urologia internationalis"},{"issue":"4","key":"598_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/02841868409136024","volume":"23","author":"B Norgaard-Pedersen","year":"1984","unstructured":"Norgaard-Pedersen B, Schultz HP, Arends J, Brincker H, Krag Jacobsen G, Lindelov B, Rorth M, Svennekjaer IL. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976\u20131980. Acta Radiol Oncol. 1984;23(4):287\u201394.","journal-title":"Acta Radiol Oncol"},{"issue":"1","key":"598_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.1986.4.1.41","volume":"4","author":"JL Grem","year":"1986","unstructured":"Grem JL, Trump DL. Reversible increase in serum alpha-fetoprotein content associated with hepatic dysfunction during chemotherapy for seminoma. J Clin Oncol. 1986;4(1):41\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"598_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0022-5347(05)67807-X","volume":"163","author":"MJ Morris","year":"2000","unstructured":"Morris MJ, Bosl GJ. Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors. J Urology. 2000;163(3):796\u2013801.","journal-title":"J Urology"},{"issue":"1","key":"598_CR36","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.clgc.2015.07.014","volume":"14","author":"C Vazeille","year":"2016","unstructured":"Vazeille C, Massard C, Loriot Y, Albiges L, Troalen F, Escudier B, Fizazi K. Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma. Clin Genitourin Cancer. 2016;14(1):e91\u20133.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"598_CR37","first-page":"1425","volume":"5","author":"T Nazeer","year":"1998","unstructured":"Nazeer T, Ro JY, Amato RJ, Park YW, Ordonez NG, Ayala AG. Histologically pure seminoma with elevated alpha-fetoprotein: a clinicopathologic study of ten cases. Oncol Rep. 1998;5(6):1425\u20139.","journal-title":"Oncol Rep"},{"issue":"11","key":"598_CR38","first-page":"354","volume":"68","author":"AC Houwert","year":"2010","unstructured":"Houwert AC, Giltay JC, Lentjes EG, Lock MT. Hereditary persistence of alpha-fetoprotein (HPAF P): review of the literature. Neth J Med. 2010;68(11):354\u20138.","journal-title":"Neth J Med"},{"issue":"6","key":"598_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ejpn.2007.04.001","volume":"11","author":"A Stray-Pedersen","year":"2007","unstructured":"Stray-Pedersen A, Borresen-Dale AL, Paus E, Lindman CR, Burgers T, Abrahamsen TG. Alpha fetoprotein is increasing with age in ataxia-telangiectasia. Eur J Paediatr Neurol. 2007;11(6):375\u201380.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"598_CR40","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/bjh.15223","volume":"184","author":"Baheyeldin Salem","year":"2018","unstructured":"Salem B, Mitchell R, DeFor TE, Tryon R, Wagner JE, MacMillan ML. Elevations in serum alpha fetoprotein levels in patients with Fanconi anaemia. Br J Haematol 2019;184(6):1032-35.","journal-title":"British Journal of Haematology"},{"issue":"11","key":"598_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jjco\/hyf094","volume":"32","author":"T Kamoto","year":"2002","unstructured":"Kamoto T, Satomura S, Yoshiki T, Okada Y, Henmi F, Nishiyama H, Kobayashi T, Terai A, Habuchi T, Ogawa O. Lectin-reactive alpha-fetoprotein (AFP-L3%) curability and prediction of clinical course after treatment of non-seminomatous germ cell tumors. Jpn J Clin Oncol. 2002;32(11):472\u20136.","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"598_CR42","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s13277-013-0904-y","volume":"34","author":"AA Terentiev","year":"2013","unstructured":"Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumour Biol. 2013;34(4):2075\u201391.","journal-title":"Tumour Biol"},{"issue":"6","key":"598_CR43","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","volume":"61","author":"ML Chang","year":"2014","unstructured":"Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407\u201317.","journal-title":"J Hepatol"},{"issue":"9","key":"598_CR44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/jgh.12612","volume":"29","author":"JJ Shim","year":"2014","unstructured":"Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014;29(9):1699\u2013705.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"598_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","volume":"96","author":"JH Hoofnagle","year":"1982","unstructured":"Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96(4):447\u20139.","journal-title":"Ann Intern Med"},{"issue":"3","key":"598_CR46","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/hep.26739","volume":"59","author":"GL Wong","year":"2014","unstructured":"Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59(3):986\u201395.","journal-title":"Hepatology"},{"issue":"1","key":"598_CR47","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/liv.12516","volume":"35","author":"GA Kim","year":"2015","unstructured":"Kim GA, Seock CH, Park JW, An J, Lee KS, Yang JE, Lim YS, Kim KM, Shim JH, Lee D, et al. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015;35(1):232\u20139.","journal-title":"Liver Int"},{"issue":"19","key":"598_CR48","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1200\/JCO.2014.56.0607","volume":"32","author":"C Albany","year":"2014","unstructured":"Albany C, Einhorn L. Pitfalls in management of patients with germ cell tumors and slight elevation of serum alpha-fetoprotein. J Clin Oncol. 2014;32(19):2114\u20135.","journal-title":"J Clin Oncol"},{"key":"598_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2016.00102","volume":"6","author":"AM Angarita","year":"2016","unstructured":"Angarita AM, Johnson CA, Fader AN, Christianson MS. Fertility Preservation: A Key Survivorship Issue for Young Women with Cancer. Front Oncol. 2016;6:102.","journal-title":"Front Oncol"},{"issue":"5","key":"598_CR50","first-page":"2607","volume":"41","author":"S Del-Pozo-Lerida","year":"2019","unstructured":"Del-Pozo-Lerida S, Salvador C, Martinez-Soler F, Tortosa A, Perucho M, Gimenez-Bonafe P. Preservation of fertility in patients with cancer (Review). Oncol Rep. 2019;41(5):2607\u201314.","journal-title":"Oncol Rep"},{"issue":"2","key":"598_CR51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/0167482X.2016.1141891","volume":"37","author":"P Mielcarek","year":"2016","unstructured":"Mielcarek P, Nowicka-Sauer K, Kozaka J. Anxiety and depression in patients with advanced ovarian cancer: a prospective study. J Psychosom Obstet Gynaecol. 2016;37(2):57\u201367.","journal-title":"J Psychosom Obstet Gynaecol"},{"issue":"2","key":"598_CR52","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ygyno.2015.11.010","volume":"140","author":"LB Huffman","year":"2016","unstructured":"Huffman LB, Hartenbach EM, Carter J, Rash JK, Kushner DM. Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. Gynecol Oncol. 2016;140(2):359\u201368.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"598_CR53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pon.4961","volume":"28","author":"Y Wang","year":"2019","unstructured":"Wang Y, Anazodo A, Logan S. Systematic review of fertility preservation patient decision aids for cancer patients. Psychooncology. 2019;28(3):459\u201367.","journal-title":"Psychooncology"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0598-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0598-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:14:42Z","timestamp":1607732082000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0598-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0598-x","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The project and consent process were approved by the Ethics Committee of Peking Union Medical College Hospital, Beijing. The written informed consent was obtained from participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The Written informed consent has been obtained from the patient for publishing this case report and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}